Leflunomide to stop CMV after stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether the drug leflunomide can prevent CMV virus reactivation after a half-matched stem cell transplant. If you have already had a successful white blood cell recovery and no sign of CMV, this might help keep you safe from the virus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are getting a stem cell transplant from a half-matched donor (haploidentical)
- You are 18 years or older
- A blood test in the last week showed no CMV virus
- Your white blood cell count has recovered after transplant (ANC of 500 or more for at least 3 days in a row)
- You start the study drug within 7 days of your white blood cell recovery
- Your liver and kidney function are working well enough
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if doctors can safely stop the anti-CMV drug letermovir earlier in stem cell transplant patients who have recovered their immune system. It focuses on patients who are at high risk for CMV but currently have no active infection.
This trial tests whether the drug letermovir can prevent cytomegalovirus (CMV) infection in people who have had a stem cell transplant. It is for adults who are CMV-positive and have not yet had a CMV infection.
This study looks at how well your immune system fights CMV (a common virus) after you stop taking a preventive medicine called Letermovir. It aims to see if your immune recovery can predict later CMV infections.
This trial tests whether taking letermovir for a longer time can prevent CMV (a common virus) from reactivating in adults with certain risk factors after a donor stem cell transplant. If you're preparing for your first transplant and have a high-risk donor or conditioning, this study may be an option.
This trial tests whether doctors can safely stop a CMV prevention medication (letermovir) earlier by using blood tests to check your immune system's strength. CMV is a virus that can become dangerous after stem cell transplant, and this study aims to prevent it while minimizing unnecessary medicine.
This trial uses a blood test to measure your immune system's ability to fight CMV, a common virus after transplant. The results will help your doctors decide if you can safely stop taking the antiviral medication letermovir earlier to avoid unnecessary side effects.
Hear when a new Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.